Abstract library

1 results for "Grosch".
#499 Effect of Everolimus on Pharmacokinetics of Octreotide LAR in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
Introduction: In RADIANT-2 (NCT00412061), Everolimus (E) plus Octreotide LAR (O) exhibited a clinically meaningful 5.1-month improvement in progression-free survival (PFS) v. placebo plus octreotide LAR (P+O) in patients (pts) with advanced neuroendocrine tumors (NET) and a history of carcinoid syndrome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Marianne E Pavel
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.